Summary
The FDA’s Roadmap to reducing animal testing in preclinical studies (April, 2025) sets out an ambitious and clear objective “to make animal studies the exception rather than the norm for preclinical safety/toxicity testing” within 3-5 years from now. Existing in silico tools can give early risk assessments of common safety issues to help reduce reliance on animal studies and contribute to this objective.
In this webinar, we’ll introduce ToxStudio®, a suite of in silico tools addressing critical preclinical safety challenges:
Libra™ – AI-powered DILI prediction
Cardiac Safety Simulator™ – Modeling and simulation platform to predict QT/proarrhythmia risk
Secondary Intelligence™ – Secondary pharmacology software to contextualize and categorize off-target risks
ToxStudio is part of Certara’s Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the shift toward adopting New Approach Methodologies (NAMs) outlined in the FDA roadmap.
Register now
Vice President, Quantitative Systems Toxicology and Safety
Will leads the QSTS team to apply computational approaches to assess the safety of pharmaceuticals and other chemicals. He is an experienced safety pharmacologist, having worked at Syntex, Quintiles and AstraZeneca. He is a former President of the Safety Pharmacology Society.
Register now
